A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

Inclusion criteria

Acceptable methods of birth control in this study are the following: * Combined hormonal (oestrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal * Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable * Placement of an intrauterine device or intrauterine hormone-releasing system * Bilateral tubal occlusion * Vasectomized partner * Complete sexual abstinence All participants: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Inclusion Criteria for Participants with Mild or Moderate Hepatic Impairment (Groups 1 and 2) Each participant with mild or moderate hepatic impairment must satisfy the following criteria to be enrolled in the study: * Participant has mild (5 to 6 points) or moderate (7 to 9 points) hepatic impairment per the Child-Pugh system (Appendix B). * Participant should be enrolled into the group corresponding to the Child-Pugh classification score that most accurately reflects the most severe hepatic disease classification within the past 6 months of signing the ICF (based on past medical history or PE observation). * If a Child-Pugh score was previously calculated and documented in the last 6 months, and it is more severe than the one calculated at Screening, then that previous value will be used for study entry purposes. If the Screening Child-Pugh score is more severe, then it will be used. If no score was calculated in the 6 months prior to Screening, then the score obtained at Screening will be used. Adequate documentation should be provided to substantiate the Child-Pugh score assigned to each participant. * Participant must be medically stable for at least 4 weeks before Screening with clinically acceptable medical history (eg, no worsening of clinical signs of hepatic impairment, or no worsening of total bilirubin or prothrombin time by more than 50%), PE, clinical laboratory tests, vital signs, and 12-lead ECGs consistent with the underlying stable hepatic impairment condition, as judged by the Investigator. * Participant with laboratory parameters that are considered clinically significant beyond those consistent with their degree of hepatic impairment may be included if, in the opinion of the Investigator and Medical Monitor, these findings will not interfere with the study or introduce additional safety risk to the participant. * Participant must be stable on a concomitant medication and/or treatment regimen (defined as not starting a new treatment/medication\[s\] or a change in the dosage or frequency of the concomitant medication\[s\] within 2 weeks before dosing with ozanimod). * Participant must have estimated creatinine clearance ≥ 50 mL/min at Screening as calculated by the Cockcroft-Gault formula. Inclusion Criteria for Matched Normal Hepatic Function Participants (Group 3) Each matched participant must satisfy the following criteria to be enrolled in the study: * Participant is in good health as determined by past medical history, PE, vital signs, ECG, and clinical laboratory safety tests. Clinical laboratory safety tests (ie, hematology, coagulation, chemistry, and urinalysis) must be within normal limits or clinically acceptable as judged by the Investigator. * Participant must match a participant in Groups 1 and/or 2, with respect to sex, age (± 10 years), weight (± 20%) and smoking status. One normal hepatic function participant can be matched to 2 hepatic impairment participants (one in Group 1 and one in Group 2), but no more than one hepatic impairment participant in the same group.